BOOK
Advanced Heart Failure, An Issue of Heart Failure Clinics, E-Book
James C. Fang | Michael M. Givertz
(2016)
Additional Information
Book Details
Abstract
This issue of the Heart Failure Clinics, edited by Drs. James Fang and Michael Givertz, is entitled "Advanced Heart Failure" and covers a wide array of topics relating to the subject. The issue will delve into the prevalence, history and prognosis of advanced heart failure; cardiorenal interactions; cardiohepatic interactions; the role of temporary mechanical circulatory support; guided therapy; the role of heart transplantation; palliative care; frailty; and novel biological techniques, among other topics.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Advanced Heart Failure\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITORS | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | v | ||
| Preface: Advanced Therapies for Advanced Heart Failure: Time to Raise Awareness\r | v | ||
| Advanced Heart Failure: Prevalence, Natural History, and Prognosis\r | v | ||
| Cardiorenal Interactions\r | v | ||
| Cardiohepatic Interactions: Implications for Management in Advanced Heart Failure\r | v | ||
| Frailty in Advanced Heart Failure\r | v | ||
| Tailoring Therapies in Advanced Heart Failure\r | vi | ||
| Temporary Percutaneous Mechanical Circulatory Support in Advanced Heart Failure\r | vi | ||
| Role of Durable Mechanical Circulatory Support for the Management of Advanced Heart Failure\r | vi | ||
| Changing Role of Heart Transplantation\r | vi | ||
| Cardiac Resynchronization Therapy and Implantable Cardioverter Defibrillator Therapy in Advanced Heart Failure\r | vii | ||
| Home Inotropes and Other Palliative Care\r | vii | ||
| Recovery Versus Remission: Clinical Insights\r | vii | ||
| Novel Biological Therapies Targeting Heart Failure: Myocardial Rejuvenation\r | vii | ||
| HEART FAILURE CLINICS\r | viii | ||
| FORTHCOMING ISSUES | viii | ||
| October 2016 | viii | ||
| January 2017 | viii | ||
| April 2017 | viii | ||
| RECENT ISSUES | viii | ||
| April 2016 | viii | ||
| January 2016 | viii | ||
| October 2015 | viii | ||
| Preface: Advanced Therapies for Advanced Heart Failure: Time to Raise Awareness\r | ix | ||
| REFERENCES | x | ||
| Advanced Heart Failure | 323 | ||
| Key points | 323 | ||
| INTRODUCTION | 323 | ||
| PREVALENCE | 324 | ||
| NATURAL HISTORY | 325 | ||
| PROGNOSIS | 327 | ||
| Clinical Factors | 327 | ||
| Right Heart Factors | 328 | ||
| Laboratory Assessment | 329 | ||
| Medication Intolerance | 330 | ||
| SUMMARY | 330 | ||
| REFERENCES | 331 | ||
| Cardiorenal Interactions | 335 | ||
| Key points | 335 | ||
| INTRODUCTION | 335 | ||
| HEART FAILURE AND RENAL FUNCTION | 336 | ||
| Epidemiology | 336 | ||
| Cardiorenal Syndrome | 336 | ||
| HOW TO ASSESS RENAL DYSFUNCTION | 336 | ||
| Serum Creatinine, Glomerular Filtration Rate, and Blood Urea Nitrogen | 336 | ||
| Novel Biomarkers | 339 | ||
| TREATMENT OF CARDIORENAL SYNDROME | 340 | ||
| Diuretics and Diuretic Response | 340 | ||
| How to Improve Diuretic Response? | 341 | ||
| Investigational Therapies | 342 | ||
| SUMMARY | 343 | ||
| REFERENCES | 343 | ||
| Cardiohepatic Interactions | 349 | ||
| Key points | 349 | ||
| HEPATIC ANATOMY AND PATHOPHYSIOLOGY | 349 | ||
| LIVER DISEASE IN ADVANCED HEART FAILURE | 351 | ||
| Diagnosis of Chronic Liver Disease in Heart Failure | 351 | ||
| Hepatic fibrosis and cirrhosis: histopathology, prevalence, and clinical characteristics | 352 | ||
| Prognosis of Liver Disease in Heart Failure | 353 | ||
| High-Risk Medications in Heart Failure and Liver Dysfunction | 353 | ||
| Hepatitis C and Its Role in Heart Failure | 353 | ||
| CHRONIC LIVER DISEASE AND ADVANCED HEART FAILURE THERAPIES | 355 | ||
| Chronic Liver Disease and Mechanical Circulatory Support | 355 | ||
| Chronic Liver Disease and Heart Transplantation | 356 | ||
| Hepatitis C and Advanced Heart Failure Therapies | 356 | ||
| Novel agents for the treatment of hepatitis C virus and their implications for advanced therapies | 357 | ||
| SUMMARY | 357 | ||
| REFERENCES | 358 | ||
| Frailty in Advanced Heart Failure | 363 | ||
| Key points | 363 | ||
| INTRODUCTION | 363 | ||
| PATHOBIOLOGY OF FRAILTY IN ADVANCED HEART FAILURE | 364 | ||
| ASSESSMENT OF FRAILTY IN ADVANCED HEART FAILURE | 365 | ||
| ROLE FOR FRAILTY ASSESSMENT IN ADVANCED HEART FAILURE | 366 | ||
| PREVALENCE AND IMPACT OF FRAILTY IN ADVANCED HEART FAILURE | 367 | ||
| CONCEPT OF FRAILTY “REVERSAL” IN ADVANCED HEART FAILURE | 369 | ||
| GENERAL STRATEGIES FOR MODIFICATION OF FRAILTY IN ADVANCED HEART FAILURE | 371 | ||
| SUMMARY AND FUTURE DIRECTIONS | 371 | ||
| REFERENCES | 372 | ||
| Tailoring Therapies in Advanced Heart Failure | 375 | ||
| Key points | 375 | ||
| OPTIMIZING MEDICAL THERAPY IN ADVANCED HF | 376 | ||
| INVASIVE HEMODYNAMIC TAILORED THERAPY | 377 | ||
| IMPLANTABLE AMBULATORY HEMODYNAMIC MONITORING | 379 | ||
| TAILORING PATHWAYS TO LEFT VENTRICULAR ASSIST DEVICE/TRANSPLANT | 380 | ||
| TAILORING TO QUALITY OF LIFE | 380 | ||
| TAILORING THE TEAM TO THE PATIENT | 380 | ||
| TAILORING EXPECTATIONS | 381 | ||
| REFERENCES | 381 | ||
| Temporary Percutaneous Mechanical Circulatory Support in Advanced Heart Failure | 385 | ||
| Key points | 385 | ||
| TEMPORARY PERCUTANEOUS DEVICE TYPES AND HEMODYNAMIC EFFECTS | 386 | ||
| Intra-aortic Balloon Pump | 388 | ||
| Impella Circulatory Support System | 389 | ||
| Tandem Heart Percutaneous Ventricular Assist Device System | 391 | ||
| Extracorporeal Membrane Oxygenation | 391 | ||
| THE CARDIOGENIC SHOCK TEAM | 394 | ||
| SUMMARY | 397 | ||
| REFERENCES | 397 | ||
| Role of Durable Mechanical Circulatory Support for the Management of Advanced Heart Failure | 399 | ||
| Key points | 399 | ||
| INTRODUCTION | 399 | ||
| ROLE OF MECHANICAL CIRCULATORY SUPPORT IN ADVANCE HEART FAILURE | 399 | ||
| CLASSIFYING MECHANICAL CIRCULATORY SUPPORT | 400 | ||
| INDICATIONS FOR DEVICE SUPPORT IN THE UNITED STATES | 400 | ||
| SURVIVAL AFTER LEFT VENTRICULAR ASSIST DEVICES | 401 | ||
| SECONDARY BENEFITS OF LEFT VENTRICULAR ASSIST DEVICE SUPPORT | 402 | ||
| COMPLICATIONS | 402 | ||
| Bleeding | 403 | ||
| Stroke | 404 | ||
| Infection | 404 | ||
| Device Thrombosis | 404 | ||
| Right Ventricular Railure | 405 | ||
| ENSURING GOOD OUTCOMES FOR LEFT VENTRICULAR ASSIST DEVICE–SUPPORTED PATIENTS | 405 | ||
| SUMMARY | 407 | ||
| REFERENCES | 407 | ||
| Changing Role of Heart Transplantation | 411 | ||
| Key points | 411 | ||
| INTRODUCTION | 411 | ||
| HEART TRANSPLANT ALLOCATION POLICY | 412 | ||
| Current System | 412 | ||
| The Need for a New Approach | 413 | ||
| Changing the Heart Allocation Policy | 413 | ||
| PRIMARY GRAFT DYSFUNCTION | 414 | ||
| Defining Primary Graft Dysfunction | 414 | ||
| Risk Factors | 414 | ||
| Management and Potential Prevention | 414 | ||
| Sensitization | 416 | ||
| Detection of Anti-HLA Antibodies | 416 | ||
| Approach to the Crossmatch | 417 | ||
| The Calculated Panel-Reactive Antibody | 418 | ||
| Approach to Desensitization | 418 | ||
| Eculizumab | 418 | ||
| SUMMARY | 420 | ||
| REFERENCES | 420 | ||
| Cardiac Resynchronization Therapy and Implantable Cardioverter Defibrillator Therapy in Advanced Heart Failure | 423 | ||
| Key points | 423 | ||
| INTRODUCTION | 423 | ||
| IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS | 425 | ||
| Background Data and Indications | 425 | ||
| Tachyarrhythmia Detection and Therapy | 425 | ||
| CARDIAC RESYNCHRONIZATION THERAPY | 426 | ||
| Landmark Trials in Cardiac Resynchronization Therapy | 427 | ||
| Improving Response to Resynchronization Therapy | 428 | ||
| Intraprocedural Optimization Strategies | 428 | ||
| Postimplant Care for the Patient Undergoing Cardiac Resynchronization Therapy | 429 | ||
| CARDIAC IMPLANTED ELECTRONIC DEVICE THERAPY IN PATIENTS WITH A LEFT VENTRICULAR ASSIST DEVICE | 430 | ||
| Ventricular Arrhythmias in the Patient with a Left Ventricular Assist Device | 431 | ||
| Role of Cardiac Resynchronization Therapy in the Patient with a Left Ventricular Assist Device | 433 | ||
| SUMMARY | 433 | ||
| REFERENCES | 433 | ||
| Home Inotropes and Other Palliative Care | 437 | ||
| Key points | 437 | ||
| INTRODUCTION | 437 | ||
| DEFINITION OF PALLIATIVE CARE | 438 | ||
| TIMING OF REFERRAL FOR PALLIATIVE CARE | 438 | ||
| PHARMACOLOGIC THERAPIES IN ADVANCED HEART FAILURE PATIENTS | 438 | ||
| Inotropes | 438 | ||
| Chronic Home Inotropes | 438 | ||
| Home Inotropic Selection | 441 | ||
| Milrinone | 441 | ||
| Dobutamine | 442 | ||
| Dopamine | 442 | ||
| Digoxin | 442 | ||
| Levosimendan | 442 | ||
| OTHER MEDICATIONS IN ADVANCED HEART FAILURE | 443 | ||
| NONPHARMACOLOGIC AND INVASIVE THERAPIES IN PALLIATIVE CARE | 443 | ||
| PALLIATIVE MEDICINE IN PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICES | 443 | ||
| DEACTIVATION OF PACEMAKERS AND DEFIBRILLATORS IN END-STAGE HEART DISEASE | 444 | ||
| HOSPICE CARE | 445 | ||
| FUTURE DIRECTIONS | 445 | ||
| SUMMARY POINTS | 445 | ||
| REFERENCES | 446 | ||
| Recovery Versus Remission | 449 | ||
| Key points | 449 | ||
| INTRODUCTION | 449 | ||
| POTENTIAL FOR RECOVERY IN RECENT-ONSET CARDIOMYOPATHIES | 450 | ||
| POTENTIAL FOR CLINICAL AND MOLECULAR RECOVERY IN CHRONIC HEART FAILURE ETIOLOGIES | 451 | ||
| Drug Therapies | 451 | ||
| β-adrenergic blockers | 451 | ||
| Renin-angiotensin-aldosterone system antagonism | 453 | ||
| Surgical Therapies | 453 | ||
| Mitral valve replacement and repair | 453 | ||
| Aortic valve replacement | 453 | ||
| Revascularization | 453 | ||
| Device Therapies | 453 | ||
| Cardiac resynchronization therapy | 453 | ||
| VENTRICULAR ASSIST DEVICES: THE EMERGING FIELD OF UNLOADING-INDUCED RECOVERY/REMISSION FOR ADVANCED HEART FAILURE PATIENTS | 454 | ||
| SUSTAINED RECOVERY | 455 | ||
| SUMMARY | 456 | ||
| REFERENCES | 456 | ||
| Novel Biological Therapies Targeting Heart Failure | 461 | ||
| Key points | 461 | ||
| INTRODUCTION | 461 | ||
| CELL-BASED THERAPIES FOR HEART FAILURE WITH REDUCED EJECTION FRACTION | 462 | ||
| Bone Marrow–Derived Mesenchymal Stem Cells | 462 | ||
| Cardiac-Derived Mesenchymal Stem Cells | 462 | ||
| Multiple Stem Cell Therapies | 464 | ||
| REPROGRAMMING SCARRING | 464 | ||
| STIMULATING MYOCYTE CELL CYCLE REENTRY | 464 | ||
| MANIPULATING CELL SIGNALING TO PROMOTE MYOCARDIAL REJUVENATION | 465 | ||
| Neuregulin 1 Beta | 465 | ||
| Stromal Cell–Derived Factor 1 | 465 | ||
| Follistatin-related Protein 1 | 465 | ||
| Biologic Vasodilators | 465 | ||
| MANIPULATING GENE EXPRESSION TO PROMOTE MYOCARDIAL REJUVENATION | 467 | ||
| Sarcoplasmic Reticulum Ca2+ ATPase | 467 | ||
| Proto-Oncogene Serine/Threonine-Protein Kinase | 467 | ||
| miR-15 | 468 | ||
| SUMMARY | 468 | ||
| REFERENCES | 468 |